Please login to the form below

Not currently logged in
Email:
Password:

Intercytex

This page shows the latest Intercytex news and features for those working in and with pharma, biotech and healthcare.

UK regenerative medicine projects get £8.5m boost

An £8.5m package of grants will be shared by 14 projects in development by companies that include Cell Medica, Intercytex and Lonza Biologics. ... The projects will be led by: Altrika, Asymptote, Cell Medica, CellSeed Europe, Cellzome, ImmunoSolv,

Latest news

  • Take off

    Turnover was zero. Intercytex uses the body's own repair mechanisms to slow down ageing. ... Intercytex has a skin replacement product for burns, and is aiming for this to replace skin grafts.

  • Merger mania hits

    The company uses human cells for its skin and hair replacement products - a market that Intercytex believes is worth some $6bn in sales. ... Intercytex currently has a venous leg ulcer treatment in phase III trials and expects to release further

  • Bright backdrop

    On the new listings AIM front, where a wave of biotech and healthcare companies are thought to be putting the final touches to their plans for a flotation, Intercytex, a

  • Up and up?

    Meanwhile, Intercytex, a firm is working on a treatment for baldness, hopes to raise around £15m through a floatation on AIM.

  • Weathering the storm

    Intercytex seeks backing for serious wound product. Intercytex, the speciality pharmaceutical and biotech firm, posted a pre-tax loss of £11.6m on sales up 34 per cent to £111, 000. ... The company's lead product is a treatment for serious wounds and

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dovetail

We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....